The preliminary mechanism study demonstrated that PROTAC 54 could efficiently degrade EGFR protein through ubiquitin proteasome pathway and inhibit phosphorylation of downstream pathways in vitro and in vivo, which indicated that PROTAC 54 exerted antitumour effect by degradation of EGFR protein in tumour tissue. The gene discussed is EGFR; the disease is neoplasm.